Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention.
作者信息
Kelly R V, Steinhubl S
机构信息
Division of Cardiology, University of North Carolina, Cardiac Catheterization Laboratory, Chapel Hill, North Carolina 27514-7075, USA.
出版信息
Heart. 2005 Jun;91 Suppl 3(Suppl 3):iii16-9. doi: 10.1136/hrt.2004.058511.
Abstract
摘要
相似文献
1
Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention.经皮冠状动脉介入治疗期间抗凝和抗血小板治疗角色的转变
Heart. 2005 Jun;91 Suppl 3(Suppl 3):iii16-9. doi: 10.1136/hrt.2004.058511.
2
Optimized combination of antiplatelet treatment and anticoagulation for percutaneous coronary intervention: the final word is not out yet!
J Invasive Cardiol. 2002 May;14(5):251-3.
3
Exclusive antiplatelet therapy for percutaneous coronary intervention.
J Am Coll Cardiol. 2009 May 19;53(20):1921-2; author reply 922-3. doi: 10.1016/j.jacc.2008.11.058.
4
Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation.
Am Heart J. 2005 Feb;149(2):E1. doi: 10.1016/j.ahj.2004.08.019.
5
[Anticoagulants and antiaggregants in ischemic heart disease].[缺血性心脏病中的抗凝剂和抗血小板剂]
G Ital Cardiol. 1990 Aug;20(8):746-57.
6
Percutaneous coronary interventions for coronary artery disease: the long and short of optimizing medical therapy.冠心病的经皮冠状动脉介入治疗：优化药物治疗的利弊
Int J Clin Pract. 2005 Sep;59(9):1070-81. doi: 10.1111/j.1742-1241.2005.00608.x.
7
Angioplasty, inflammation, and antiplatelet agents.血管成形术、炎症与抗血小板药物
Am Heart J. 2003 Apr;145(4):563-6. doi: 10.1067/mhj.2003.66.
8
The good, the bad, and the ugly: triple therapy after PCI in patients requiring chronic anticoagulation.
Eur Heart J. 2007 Mar;28(6):657-8. doi: 10.1093/eurheartj/ehl576. Epub 2007 Mar 1.
9
Options and outcomes with different antiplatelet strategies during primary percutaneous coronary intervention.
Eur Heart J. 2009 Jul;30(14):1687-9. doi: 10.1093/eurheartj/ehp191. Epub 2009 May 9.
10
Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience.经皮冠状动脉介入治疗后房颤患者的抗凝和/或抗血小板治疗。单中心经验。
Med Klin (Munich). 2008 Sep 15;103(9):628-32. doi: 10.1007/s00063-008-1101-4. Epub 2008 Sep 24.
本文引用的文献
1
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.在氯吡格雷预处理后进行的阿昔单抗用于择期经皮冠状动脉介入治疗的临床试验。
N Engl J Med. 2004 Jan 15;350(3):232-8. doi: 10.1056/NEJMoa031859.
2
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.联合使用依诺肝素和糖蛋白IIb/IIIa拮抗剂治疗急性冠状动脉综合征：依诺肝素-3全国研究者协作研究（NICE-3）的最终结果
Am Heart J. 2003 Oct;146(4):628-34. doi: 10.1016/S0002-8703(03)00165-0.
3
Extension of increased atherosclerotic wall thickness into high shear stress regions is associated with loss of compensatory remodeling.
Circulation. 2003 Jul 8;108(1):17-23. doi: 10.1161/01.CIR.0000078637.21322.D3. Epub 2003 Jun 23.
4
What is the role for improved long-term antiplatelet therapy after percutaneous coronary intervention?经皮冠状动脉介入治疗后改进长期抗血小板治疗的作用是什么？
Am Heart J. 2003 Jun;145(6):971-8. doi: 10.1016/S0002-8703(03)00104-2.
5
A guide to therapeutic decision-making in patients with non-ST-segment elevation acute coronary syndromes.
J Am Coll Cardiol. 2003 Feb 19;41(4 Suppl S):S123-9. doi: 10.1016/s0735-1097(02)02689-x.
6
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.比伐卢定与临时糖蛋白IIb/IIIa受体阻滞剂联用与肝素及计划使用糖蛋白IIb/IIIa受体阻滞剂在经皮冠状动脉介入治疗中的比较：REPLACE-2随机试验
JAMA. 2003 Feb 19;289(7):853-63. doi: 10.1001/jama.289.7.853.
7
Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.静脉注射糖蛋白IIb/IIIa受体拮抗剂可降低经皮冠状动脉介入治疗后的死亡率。
J Am Coll Cardiol. 2003 Jan 1;41(1):26-32. doi: 10.1016/s0735-1097(02)02666-9.
8
Scientific and therapeutic advances in antiplatelet therapy.抗血小板治疗的科学与治疗进展。
Nat Rev Drug Discov. 2003 Jan;2(1):15-28. doi: 10.1038/nrd985.
9
Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease.血小板ADP受体拮抗剂氯吡格雷与AR-C69931MX对缺血性心脏病患者药效学作用的比较。
Platelets. 2002 Nov;13(7):407-13. doi: 10.1080/0953710021000024402.
10
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention.在择期经皮冠状动脉介入治疗中使用独特的低剂量静脉注射依诺肝素。
J Am Coll Cardiol. 2002 Dec 4;40(11):1943-50. doi: 10.1016/s0735-1097(02)02531-7.
Zotero 插件